Clinical Trial Detail

NCT ID NCT02262741
Title A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors MedImmune LLC
Indications

hypopharynx cancer

oral cavity cancer

oropharynx cancer

laryngeal squamous cell carcinoma

head and neck squamous cell carcinoma

Therapies

Tremelimumab

Durvalumab

Age Groups: adult

No variant requirements are available.